Maria Thompson

Last month we ran a series of blog posts about next generation sequencing. Among the topics discussed were the limitations of next generation...

We’ve covered many different aspects of pharmaceutical innovation, ranging from organizational structure, patents, and incubators, but are there...

Here at Scientist, for the past few weeks we’ve been running a series of blog posts about stem cells discussing why iPS make an attractive research...

In our previous post on stem cells, we discussed how human-derived induced pluripotent stem cells (iPS) are being used to model “disease in a...

Carlsbad, CA is soon to be home to San Diego’s own community laboratory space. Much along the lines of Genspace in NYC and BioCurious in Sunnyvale...

Pharmaceutical innovation doesn’t just happen because a lot of money is thrown at it or the company has been restructured. It requires a setting...

One welcome result of the pharmaceutical innovation crisis is a shift from blockbuster drugs to rare disease drugs. We are doing our own part to...

Pharmaceutical innovation is a broad term that can encompass and affect any step of the drug discovery and development process, so how exactly are...

With the fiscal cliff negotiations over for now, we turn our attention to the patent cliff. A lot of industry watchers and participants often...

We’ve just wrapped up the Tri-State Open Science Challenge, the second that we’ve held. We are proud to announce four winners awarding $16,000...